Literature DB >> 8000723

Antiemetics in children receiving cancer chemotherapy.

A L Billett1, S E Sallan.   

Abstract

Nausea and vomiting are debilitating side effects that often accompany the administration of chemotherapy and may lead to adverse physiological and psychological effects. Chemotherapy agents usually stimulate the chemoreceptor trigger zone, which then sends signals to the vomiting center in the medullary lateral reticular formation. The neurochemistry of vomiting involves serotonin and serotonin S3 receptors. Nausea and vomiting are difficult to treat once they have occurred, and prior poor antiemetic control may lead to future anticipatory nausea and vomiting. Thus, good antiemetic regimens must be prophylactic, scheduled, and individualized. Specific regimens must be adjusted to account for the emetogenic potential of the chemotherapy drug(s) being administered and the individual patient's preferences. The major classes of antiemetics include serotonin S3 receptor antagonists, phenothiazines and metoclopramide. Steroids are ineffective antiemetics alone but good potentiators of other antiemetics. We usually recommend a serotonin S3 receptor antagonist alone for less emetogenic regimens or in conjunction with dexamethasone for more emetogenic regimens. For breakthrough vomiting, we usually add lorazepam and/or scopolamine.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8000723     DOI: 10.1007/BF00365578

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  30 in total

1.  Identification and distribution of 5-HT3 recognition sites within the human brainstem.

Authors:  J M Barnes; N M Barnes; B Costall; J F Deakin; J W Ironside; G J Kilpatrick; R J Naylor; J A Rudd; M D Simpson; P Slater
Journal:  Neurosci Lett       Date:  1990-03-26       Impact factor: 3.046

2.  Domperidone or metoclopramide in preventing chemotherapeutically induced nausea and vomiting.

Authors:  I L Swann; E N Thompson; K Qureshi
Journal:  Br Med J       Date:  1979-11-10

3.  Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.

Authors:  L X Cubeddu; I S Hoffmann; N T Fuenmayor; A L Finn
Journal:  N Engl J Med       Date:  1990-03-22       Impact factor: 91.245

4.  Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol.

Authors:  H Ekert; K D Waters; I H Jurk; J Mobilia; P Loughnan
Journal:  Med J Aust       Date:  1979-12-15       Impact factor: 7.738

5.  5-HT3 antagonist ondansetron--an effective outpatient antiemetic in cancer treatment.

Authors:  C R Pinkerton; D Williams; C Wootton; S T Meller; T J McElwain
Journal:  Arch Dis Child       Date:  1990-08       Impact factor: 3.791

6.  A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. International Emesis Study Group.

Authors:  S Kaasa; S Kvaløy; M A Dicato; F Ries; J V Huys; E Royer; L Carruthers
Journal:  Eur J Cancer       Date:  1990-03       Impact factor: 9.162

7.  Intravenous metoclopramide. An effective antiemetic in cancer chemotherapy.

Authors:  S B Strum; J E McDermed; R W Opfell; L P Riech
Journal:  JAMA       Date:  1982-05-21       Impact factor: 56.272

8.  5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret.

Authors:  G A Higgins; G J Kilpatrick; K T Bunce; B J Jones; M B Tyers
Journal:  Br J Pharmacol       Date:  1989-05       Impact factor: 8.739

9.  Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone.

Authors:  F Roila; M Tonato; F Cognetti; E Cortesi; G Favalli; M Marangolo; D Amadori; M A Bella; V Gramazio; D Donati
Journal:  J Clin Oncol       Date:  1991-04       Impact factor: 44.544

10.  A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy.

Authors:  A E Chang; D J Shiling; R C Stillman; N H Goldberg; C A Seipp; I Barofsky; S A Rosenberg
Journal:  Cancer       Date:  1981-04-01       Impact factor: 6.860

View more
  2 in total

1.  Antiemetic treatment for cancer chemotherapy: problems and progress.

Authors:  R J Gralla
Journal:  Support Care Cancer       Date:  1994-09       Impact factor: 3.603

Review 2.  Options for the prevention and management of acute chemotherapy-induced nausea and vomiting in children.

Authors:  L Lee Dupuis; Paul C Nathan
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.